Andrea Haitel

List of Publications by Year
in descending order

58 papers	1,348 citations	331259 21 h-index	377514 34 g-index
58 all docs	58 docs citations	58 times ranked	2369 citing authors

#	Article	IF	Citations
1	Comparison of Permethrin-Based Treatment Strategies against Scabies in Infants and Young Children. Journal of Pediatrics, 2022, 245, 184-189.	0.9	6
2	Molecular and Pharmacological Bladder Cancer Therapy Screening: Discovery of Clofarabine as a Highly Active Compound. European Urology, 2022, 82, 261-270.	0.9	11
3	T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Nonâ€“muscle-invasive Bladder Cancer Spectrum. European Urology Focus, 2022, , .	1.6	4
4	Thyroid and androgen receptor signaling are antagonized by Î¼â€Crystallin in prostate cancer. International Journal of Cancer, 2021, 148, 731-747.	2.3	17
5	Visibility of significant prostate cancer on multiparametric magnetic resonance imaging (MRI)â€”do we still need contrast media?. European Radiology, 2021, 31, 3754-3764.	2.3	10
6	More than ancillary records: clinical implications of renal pathology examination in tumor nephrectomy specimens. Journal of Nephrology, 2021, 34, 1833-1844.	0.9	2
7	European Association of Urology (EAU) Prognostic Factor Risk Groups for Nonâ€“muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. European Urology, 2021, 79, 480-488.	0.9	198
8	Association of super-extended lymphadenectomy at radical cystectomy with perioperative complications and re-hospitalization. World Journal of Urology, 2020, 38, 121-128.	1.2	10
9	Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 440-448.	0.8	27
10	PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 496-505.	0.8	6
11	Discovery of Molecular DNA Methylation-Based Biomarkers through Genome-Wide Analysis of Response Patterns to BCG for Bladder Cancer. Cells, 2020, 9, 1839.	1.8	11
12	The prognostic impact of tumour NSD2 expression in advanced prostate cancer. Biomarkers, 2020, 25, 268-273.	0.9	6
13	<scp>STAT</scp> 3 â€dependent analysis reveals <scp>PDK</scp> 4 as independent predictor of recurrence in prostate cancer. Molecular Systems Biology, 2020, 16, e9247.	3.2	38
14	The prognostic value of the urokinase-plasminogen activator system (uPA) in bladder cancer patients treated with radical cystectomy (RC). Urologic Oncology: Seminars and Original Investigations, 2020, 38, 423-432.	0.8	4
15	The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 685.e17-685.e25.	0.8	2
16	Prevalence and Prognostic Value of the Polymorphic Variant 1245A>C of HSD3B1 in Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2019, 17, 389-394.	0.9	3
17	Prospective evaluation of the performance of [68Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2169-2177.	3.3	30
18	Prognostic role of the urokinase plasminogen activator (uPA) system in patients with nonmuscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 774-783.	0.8	5

#	Article	IF	Citations
19	Urinary expression of genes involved in DNA methylation and histone modification for diagnosis of bladder cancer in patients with asymptomatic microscopic haematuria. Oncology Letters, 2019, 18, 57-62.	0.8	4
20	Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study. World Journal of Urology, 2019, 37, 2419-2427.	1.2	9
21	Caveolin-1 Expression in Upper Tract Urothelial Carcinoma. European Urology Focus, 2019, 5, 97-103.	1.6	3
22	HER2 and TOP2A Gene Amplification and Protein Expression in Upper Tract Urothelial Carcinomas. Pathology and Oncology Research, 2018, 24, 575-581.	0.9	8
23	Prognostic Role of N-cadherin Expression in Patients With Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, e73-e78.	0.9	13
24	Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice. BJU International, 2018, 121, 84-92.	1.3	22
25	A urinary microRNA (miR) signature for diagnosis of bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 531.e1-531.e8.	0.8	41
26	Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 343.e1-343.e8.	0.8	4
27	Cancer stage and pack-years, but not p16 or HPV, are relevant for survival in hypopharyngeal and laryngeal squamous cell carcinomas. European Archives of Oto-Rhino-Laryngology, 2018, 275, 1837-1843.	0.8	22
28	HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC). World Journal of Urology, 2017, 35, 251-259.	1.2	33
29	Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study. World Journal of Urology, 2017, 35, 113-120.	1.2	22
30	Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy. World Journal of Urology, 2017, 35, 121-130.	1.2	37
31	Prognostic role of N-cadherin expression in patients with nonâ€“muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 264-271.	0.8	30
32	Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 356-362.	0.8	4
33	HSP90 is necessary for the ACK1-dependent phosphorylation of STAT1 and STAT3. Cellular Signalling, 2017, 39, 9-17.	1.7	32
34	Frequency and Prognostic Value of PTEN Loss in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. Journal of Urology, 2017, 198, 1269-1277.	0.2	5
35	Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma. Journal of Urology, 2017, 198, 1253-1262.	0.2	58
36	Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma: a multi-institutional study. World Journal of Urology, 2017, 35, 1073-1080.	1.2	12

#	Article	IF	Citations
37	Validation of Preoperative Risk Grouping of the Selection of Patients Most Likely to Benefit From Neoadjuvant Chemotherapy Before Radical Cystectomy. Clinical Genitourinary Cancer, 2017, 15, e267-e273.	0.9	33
38	Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy. Bladder Cancer, 2017, 3, 161-169.	0.2	12
39	The Phenotypic Characterization of the Human Renal Mononuclear Phagocytes Reveal a Co-Ordinated Response to Injury. PLoS ONE, 2016, 11, e0151674.	1.1	7
40	Association of human telomerase reverse transcriptase gene polymorphisms, serum levels, and telomere length with renal cell carcinoma risk and pathology. Molecular Carcinogenesis, 2016, 55, 1458-1466.	1.3	33
41	Intraductal carcinoma of prostate reporting practice: a survey of expert European uropathologists. Journal of Clinical Pathology, 2016, 69, 852-857.	1.0	29
42	Serum Adiponectin Predicts Cancer-specific Survival of Patients with Renal Cell Carcinoma. European Urology Focus, 2016, 2, 197-203.	1.6	15
43	The effect of HER2 status on oncological outcomes of patients with invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 533.e1-533.e10.	0.8	17
44	Altered Expression of the Transcription Factor Forkhead Box A1 (FOXA1) Is Associated With Poor Prognosis in Urothelial Carcinoma of the Upper Urinary Tract. Urology, 2016, 94, 314.e1-314.e7.	0.5	16
45	Dynamic Prognostication Using Conditional Recurrence and Progression Estimates for Patients with Nonmuscle Invasive Bladder Cancer. Journal of Urology, 2016, 196, 46-51.	0.2	13
46	Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent. World Journal of Urology, 2016, 34, 1155-1161.	1.2	4
47	Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal cell carcinoma reveals <scp>cM</scp>et as a negative prognostic factor. Histopathology, 2015, 67, 799-805.	1.6	10
48	Carbonic Anhydrase IX as a Diagnostic Urinary Marker for Urothelial Bladder Cancer. European Urology, 2015, 68, 552-554.	0.9	29
49	STAT3 regulated ARF expression suppresses prostate cancer metastasis. Nature Communications, 2015, 6, 7736.	5.8	136
50	Histopathology and prognosis of de novo bladder tumors following solid organ transplantation. World Journal of Urology, 2015, 33, 2087-2093.	1.2	8
51	Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: A multi-institutional study. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 495.e15-495.e22.	0.8	15
52	Multi-institutional Validation of the Predictive Value of Ki-67 in Patients with High Grade Urothelial Carcinoma of the Upper Urinary Tract. Journal of Urology, 2015, 193, 1486-1493.	0.2	38
53	The preoperative prognostic nutritional index is an independent predictor of survival in patients with renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 68.e1-68.e7.	0.8	56
54	Associations Between Presenting Symptoms, Clinicopathological Parameters, and Prognosis in a Contemporary Series of Patients With Renal Cell Carcinoma. Korean Journal of Urology, 2014, 55, 505.	1.2	12

#	Article	IF	Citations
55	Insulin-like Growth Factor Messenger RNA-binding Protein 3 Expression Helps Prognostication in Patients with Upper Tract Urothelial Carcinoma. European Urology, 2014, 66, 379-385.	0.9	27
56	Evaluation of the Prognostic Significance of Altered Mammalian Target of Rapamycin Pathway Biomarkers in Upper Tract Urothelial Carcinoma. Urology, 2014, 84, 1134-1140.	0.5	18
57	Prospective evaluation of diffusion-weighted MRI of the bladder as a biomarker for prediction of bladder cancer aggressiveness. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1166-1171.	0.8	42
58	Quantitative Apparent Diffusion Coefficient Measurements Obtained by 3-Tesla MRI Are Correlated with Biomarkers of Bladder Cancer Proliferative Activity. PLoS ONE, 2014, 9, e106866.	1.1	29